Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

About Five Prime Therapeutics

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company's product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $51.84
  • 50 Day Moving Average: $48.45
  • 200 Day Moving Average: $44.85
  • 52-Week Range: $15.00 - $55.00
  • Trailing P/E Ratio: 5.90
  • Foreward P/E Ratio: -15.04
  • P/E Growth: 0.78
  • Market Cap: $1.41B
  • Outstanding Shares: 26,923,000
  • Beta: 4.51
Profitability:
  • Net Margins: 63.88%
  • Return on Equity: 69.59%
  • Return on Assets: 56.21%
Debt:
  • Current Ratio: 10.88%
  • Quick Ratio: 10.88%
Additional Links:
Companies Related to Five Prime Therapeutics:

Analyst Ratings

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $53.60 (2.11% upside)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
DateFirmActionRatingPrice TargetDetails
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00View Rating Details
8/5/2016Jefferies GroupSet Price TargetBuy$41.00 -> $60.00View Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
5/19/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$48.00View Rating Details
4/12/2016BMO Capital MarketsInitiated CoverageMarket Perform$50.00View Rating Details
12/4/2015Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
7/31/2015Citigroup Inc.Initiated CoverageNeutral -> Buy$33.00View Rating Details
5/13/2015GuggenheimInitiated CoverageBuy$31.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.53)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.10)($0.55)$4.65 millionViewN/AView Earnings Details
11/10/2014($0.40)($0.33)ViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)ViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)ViewListenView Earnings Details
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
Current Year EPS Consensus Estimate: $-2.07 EPS
Next Year EPS Consensus Estimate: $-3.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.87)($0.46)($0.62)
Q2 20162($0.76)($0.57)($0.67)
Q3 20163($0.80)($0.53)($0.65)
Q4 20163($1.38)($0.59)($0.88)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 86.49%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2016William R RingoDirectorSell500$44.20$22,100.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$50.77$25,385.00View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.50View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
DateHeadline
News IconAnalyst Coverage: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - NewsDen (NASDAQ:FPRX)
newsden.net - October 1 at 10:29 AM
News IconFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Updated Broker Price Targets - The De Soto Edge (NASDAQ:FPRX)
desotoedge.com - September 29 at 10:06 AM
News IconNotable Technical Move: Five Prime Therapeutics Inc Forms Bullish Wedge Up Pattern; Strong Momentum for Buyers ... - Chester News (NASDAQ:FPRX)
www.chesterindependent.com - September 28 at 4:56 PM
News IconFive Prime Therapeutics to Present at the LEERINK Partners Rare Disease Immuno-Oncology Roundtable - EconoTimes (NASDAQ:FPRX)
www.econotimes.com - September 24 at 4:48 PM
publicnow.com logoFive Prime Therapeutics to Present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable (NASDAQ:FPRX)
www.publicnow.com - September 22 at 5:08 PM
finance.yahoo.com logo4:42 pm Five Prime Therapeutics promotes Aron Knickerbocker to Chief Operating Officer, Francis Sarena to Chief Strategy Officer and Luis Borges, Ph.D., to Senior Vice President, Resea (NASDAQ:FPRX)
finance.yahoo.com - September 21 at 9:19 AM
publicnow.com logoFive Prime Therapeutics Announces Key Executive Promotions (NASDAQ:FPRX)
www.publicnow.com - September 21 at 9:19 AM
feeds.reuters.com logoBRIEF-Five Prime Therapeutics says Aron Knickerbocker promoted to COO (NASDAQ:FPRX)
feeds.reuters.com - September 20 at 5:19 PM
News IconStock Pattern: How Analysts Feel About Five Prime Therapeutics Inc After Forming Wedge Up Chart Pattern? - Chester News (NASDAQ:FPRX)
www.chesterindependent.com - September 18 at 9:41 AM
globenewswire.com logoFive Prime Therapeutics (Nasdaq: FPRX) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release) (NASDAQ:FPRX)
globenewswire.com - September 17 at 4:54 PM
publicnow.com logoFive Prime Therapeutics (Nasdaq: FPRX) to Ring The Nasdaq Stock Market Opening Bell (NASDAQ:FPRX)
www.publicnow.com - September 16 at 4:58 PM
News IconWhat's Next for Five Prime Therapeutics Inc After Today's Huge ... - Chester News (NASDAQ:FPRX)
www.chesterindependent.com - September 15 at 8:07 AM
4-traders.com logoFIVE PRIME THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:FPRX)
www.4-traders.com - September 14 at 5:09 PM
biz.yahoo.com logoFIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:FPRX)
biz.yahoo.com - September 14 at 5:09 PM
investornewswire.com logoCan Shares Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Hit $60 - Investor Newswire (NASDAQ:FPRX)
www.investornewswire.com - September 12 at 4:56 PM
News IconTelemetry Investments L.l.c. Lowers stake in Five Prime Therapeutics Inc (FPRX) - National Daily Press (NASDAQ:FPRX)
www.nationaldailypress.com - September 10 at 4:45 PM
News IconTelemetry Investments L.l.c. Lowers stake in Five Prime Therapeutics Inc (FPRX) (NASDAQ:FPRX)
www.nationaldailypress.com - September 10 at 9:39 AM
capitalcube.com logoFive Prime Therapeutics, Inc. – Value Analysis (NASDAQ:FPRX) : September 9, 2016 (NASDAQ:FPRX)
www.capitalcube.com - September 9 at 4:56 PM
News IconStock Showing Gains in Today's Session: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Post News (NASDAQ:FPRX)
www.kentuckypostnews.com - September 8 at 4:59 PM
News IconPlacing Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares Under the Microscope - Post News (NASDAQ:FPRX)
www.kentuckypostnews.com - September 8 at 8:57 AM
capitalcube.com logoFive Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : September 8, 2016 (NASDAQ:FPRX)
www.capitalcube.com - September 8 at 8:57 AM
publicnow.com logoFive Prime Therapeutics to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:FPRX)
www.publicnow.com - September 6 at 5:01 PM
News IconStock in Review: Taking a Closer Look at Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares - Post News (NASDAQ:FPRX)
www.kentuckypostnews.com - September 1 at 5:29 AM
insidermonkey.com logoWhy Do Hedge Funds Like Five Prime Therapeutics? - Insider Monkey (blog) (NASDAQ:FPRX)
www.insidermonkey.com - August 31 at 5:37 PM
News IconWhy Do Hedge Funds Like Five Prime Therapeutics? (NASDAQ:FPRX)
feedproxy.google.com - August 31 at 12:54 PM
investornewswire.com logoCan Shares Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Get To $60? - Investor Newswire (NASDAQ:FPRX)
www.investornewswire.com - August 29 at 5:01 PM
capitalcube.com logoFive Prime Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FPRX-US : August 25, 2016 (NASDAQ:FPRX)
www.capitalcube.com - August 25 at 10:04 AM
capitalcube.com logoETF’s with exposure to Five Prime Therapeutics, Inc. : August 23, 2016 (NASDAQ:FPRX)
www.capitalcube.com - August 23 at 5:12 PM
investornewswire.com logoWill Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Hit $60 Price Target? - Investor Newswire (NASDAQ:FPRX)
www.investornewswire.com - August 15 at 5:14 PM
fidaily.com logoFive Prime Therapeutics, Inc. (FPRX) Ownership Increased by Fmr ... - Finance Daily (NASDAQ:FPRX)
www.fidaily.com - August 12 at 8:03 AM
capitalcube.com logoETF’s with exposure to Five Prime Therapeutics, Inc. : August 11, 2016 (NASDAQ:FPRX)
www.capitalcube.com - August 11 at 5:17 PM
finance.yahoo.com logoFIVE PRIME THERAPEUTICS INC Financials (NASDAQ:FPRX)
finance.yahoo.com - August 11 at 5:17 PM
seekingalpha.com logoFive Prime Therapeutics Could Be The Ace Up The Sleeve Of Bristol-Myers Squibb (NASDAQ:FPRX)
seekingalpha.com - August 9 at 9:26 PM
forbes.com logoMonday's ETF Movers: XOP, XBI (NASDAQ:FPRX)
www.forbes.com - August 9 at 3:49 PM
capitalcube.com logoFive Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:FPRX)
www.capitalcube.com - August 9 at 3:49 PM
streetupdates.com logoAnalysts Spotlight: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - Street Updates (NASDAQ:FPRX)
www.streetupdates.com - August 9 at 8:01 AM
feeds.benzinga.com logoMonday's Market Wrap: Stocks Begin Week With Minor Losses (NASDAQ:FPRX)
feeds.benzinga.com - August 8 at 7:03 PM
News IconWorth Watching Stocks to Track: Five Prime Therapeutics Inc (NASDAQ:FPRX), US Foods Holding Corp (NYSE:USFD) - NYSE Journal (press release) (NASDAQ:FPRX)
stockznews.com - August 6 at 5:23 PM
News IconFive Prime Therapeutics Inc. 2Q earnings released (NASDAQ: FPRX) - BNB Daily (blog) (NASDAQ:FPRX)
www.baseball-news-blog.com - August 5 at 5:10 PM
biz.yahoo.com logoFIVE PRIME THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:FPRX)
biz.yahoo.com - August 5 at 5:09 PM
finance.yahoo.com logoEdited Transcript of FPRX earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:FPRX)
finance.yahoo.com - August 5 at 5:09 PM
equities.com logoFive Prime Therapeutics Inc. (FPRX) is Trading Lower on Unusual Volume for August 02 - Equities.com (NASDAQ:FPRX)
www.equities.com - August 5 at 5:28 AM
equities.com logoFive Prime Therapeutics Inc. (FPRX) is Trading Higher on Unusual ... - Equities.com (NASDAQ:FPRX)
www.equities.com - August 5 at 5:28 AM
finance.yahoo.com logoFive Prime Therapeutics posts 2Q loss - Yahoo Finance (NASDAQ:FPRX)
finance.yahoo.com - August 4 at 10:50 PM
sg.finance.yahoo.com logoFive Prime Therapeutics posts 2Q loss (NASDAQ:FPRX)
sg.finance.yahoo.com - August 4 at 10:50 PM
prnewswire.com logoResearch Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma (NASDAQ:FPRX)
www.prnewswire.com - August 4 at 5:24 PM
twst.com logoFive Prime Therapeutics Inc.: Five Prime Announces Second Quarter 2016 Results and Provides Business Update (NASDAQ:FPRX)
www.twst.com - August 4 at 5:24 PM
publicnow.com logoFive Prime Announces Second Quarter 2016 Results and Provides Business Update (NASDAQ:FPRX)
www.publicnow.com - August 4 at 5:24 PM
equities.com logoFive Prime Therapeutics Inc. (FPRX) Hits New 52-week High During August 01 Session - Equities.com (NASDAQ:FPRX)
www.equities.com - August 4 at 5:19 AM
nasdaq.com logoCommit To Purchase Five Prime Therapeutics At $35, Earn 9.7% Annualized Using Options - Nasdaq (NASDAQ:FPRX)
www.nasdaq.com - August 2 at 10:40 PM

Social

Five Prime Therapeutics (NASDAQ:FPRX) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff